In Defense of Johnson & Johnson: Half a Century of Increasing Dividends

Bad news seems to be hitting Johnson & Johnson (JNJ) from all angles these days, and much of it is wholly justified, but many fail to realize the long term reasons for holding this stock and buying more on weakness. JNJ operates in the medical device, prescription pharmaceuticals, and consumer health products. It’s an industry with many a setback but JNJ has been doing this since 1886 and has learned to deal with adversity. Listed below are some of the issues that JNJ investors need to be concerned with, but should not ultimately defer you from purchasing the stock. Product Recalls The Journal has put together a nice list of all of the recent recalls on the docket for JNJ. Yes, it is extremely disconcerting. The most recent developments are from subsidiaries, Animus (insulin pumps) and Cordis (factory in Puerto Rico in violation of FDA procedures). The Cordis issue is... Read more

Older articles featuring JNJ: